Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Operations (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash from Operations for 16 consecutive years, with 179689000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations changed N/A to 179689000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 512102000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 510009000.0 for FY2025, 28.83% down from the prior year.
  • Cash from Operations for Q4 2025 was 179689000.0 at Cytokinetics, down from 131600000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 26811000.0 in Q1 2022, with the low at 179689000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 88116470.59, with a median of 96205000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations tumbled 369.85% in 2021, then grew 24.6% in 2023.
  • Over 5 years, Cash from Operations stood at 44737000.0 in 2021, then crashed by 119.48% to 98190000.0 in 2022, then grew by 24.6% to 74037000.0 in 2023, then crashed by 37.09% to 101500000.0 in 2024, then plummeted by 77.03% to 179689000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 179689000.0, 131600000.0, and 101500000.0 for Q4 2025, Q1 2025, and Q3 2024 respectively.